FEEVA is a bold new project by the Kirby Institute and the Australian Living Evidence Collaboration.

Working with expert researchers, vaccine developers, regulators, and evidence synthesisers, this project will develop a framework of evidence and consensus based practical tools for the planning and assessment of indirect evidence for vaccines.

www.livingevidence.org.au/research-initiatives/about-feeva

FEEVA
A Framework for Evidence Evaluation in Vaccine Assessment

Australian Living Evidence Collaboration
UNSW Kirby Institute

Context

As a scientific community, we have tools for assessing the reliability, usefulness and certainty of data about vaccine effectiveness produced by randomised control trials (RCTs).

However, sometimes it is not feasible to conduct an RCT to test a vaccine, in which case other study types (like animal models, in vitro assays, natural history studies and human challenge studies) can be used to provide indirect evidence for vaccine effectiveness.

We don't currently have agreed tools for evaluating these kinds of studies; it's not always clear how to assess the results, leading to inconsistent interpretations.

Goals

The overall goal of the FEEVA project is to develop consensus tools for assessing evidence for vaccines, beginning with animal models, and then for natural history studies, in vitro assays and human challenge studies (CHIM). This will be achieved by convening four Expert Panels, one for each focus area.





Based on a review of evidence, the Expert Panels will propose criteria for assessing each study type, which will be reviewed by a Consultation Panel to produce a framework for evidence evaluation. The project will be overseen by a Steering Committee.

FEEVA

Key Contacts:
Professor Miles Davenport (Kirby Institute)
Professor Tari Turner (ALEC)
To express your interest or to find out more email FEEVA@kirby.unsw.edu.au

Australian Living Evidence Collaboration
Powered by Monash University

UNSW Kirby Institute

wellcome CEPI

This project is supported by funding from the Wellcome Trust and the Coalition for Epidemic Preparedness Innovations